RPG Life Sciences Q3 FY26 Revenue Up 4.2% YoY to ₹180 Cr; EBITDA Margin at 24%
RPG Life Sciences reported Q3 FY26 revenue of ₹180.0 crores, a 4.2% year-on-year increase. The company maintained an EBITDA margin of 24.0%. For 9M FY26, revenue grew 4.0% year-on-year to ₹530.6 crores. The Domestic Formulations business showed growth of 11.8% in 9M FY26, outpacing the Indian Pharmaceutical Market.
The announcement details solid financial performance with YoY revenue growth and positive business commentary, indicating a moderate impact on investor perception and company valuation.
The company reported a year-on-year increase in revenue and maintained a healthy EBITDA margin, with positive commentary from the Managing Director regarding business traction and future outlook.
RPG Life Sciences Limited announced its unaudited financial results for the third quarter ended December 31, 2025. The company reported a revenue from operations of ₹180.0 crores for Q3 FY26, marking a 4.2% year-on-year increase from ₹172.7 crores in the same period last year. Quarter-on-quarter, revenue stood at ₹180.0 crores compared to ₹181.7 crores.
For the nine-month period of FY26 (9M FY26), the revenue grew by 4.0% year-on-year to ₹530.6 crores from ₹510.3 crores in the previous year. The company maintained a healthy EBITDA margin of 24.0% in Q3 FY26.
Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., commented on the results, stating, “Q3 reflects continued traction across our core businesses supported by disciplined execution and deliberate portfolio actions. Our Domestic Formulations business delivered growth ahead of the Indian Pharmaceutical Market, recording a growth of 11.8% in 9M FY26 compared to the IPM growth of 8.2%, driven by strong brand performance, improved field effectiveness, and sharper customer engagement. Our approach remains firmly rooted in quality and improving patient outcomes.” He added, “Looking ahead, we remain committed to building a future-ready pharmaceutical enterprise — one that is resilient, innovation-led, and people-first, creating sustainable value for patients, partners, and stakeholders.”
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.